Sangamo Therapeutics (SGMOQ) Cash from Operations Growth (1y) (2011 - 2025)
Powered by 
Analysis
Sangamo Therapeutics (SGMOQ) Cash from Operations Growth (1y) (2011 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.28 Bn | 9.43 Bn | 112.79 Mn | 41.84% |
| 2 | CRISPR Therapeutics AG | 5.20 Bn | 5.20 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.76 Bn | 3.46 Bn | 55.72 Mn | 9.83% |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | -58.33% |
| 5 | uniQure | 3.07 Bn | 3.07 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.67 Bn | 2.67 Bn | - | - |
| 7 | Precigen | 2.43 Bn | 2.43 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.34 Bn | 1.54 Bn | 251.87 Mn | -24.59% |
| 9 | Vericel | 2.00 Bn | 1.83 Bn | 56.40 Mn | 97.11% |
| 10 | Sangamo Therapeutics | 43.15 Mn | 22.20 Mn | - | -628.23% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -628.23% |
| Sep 30, 2025 | -342.35% |
| Jun 30, 2025 | 32.46% |
| Mar 31, 2025 | 46.27% |
| Dec 31, 2024 | 93.37% |
| Sep 30, 2024 | 124.86% |
| Jun 30, 2024 | 55.72% |
| Mar 31, 2024 | 26.60% |
| Dec 31, 2023 | 11.41% |
| Sep 30, 2023 | 11.80% |
| Jun 30, 2023 | -12.46% |
| Mar 31, 2023 | -12.42% |
| Dec 31, 2022 | -8.22% |
| Sep 30, 2022 | 9.76% |
| Jun 30, 2022 | -2.70% |
| Mar 31, 2022 | 13.97% |
| Dec 31, 2021 | -1,127.33% |
| Sep 30, 2021 | -279.70% |
| Jun 30, 2021 | -132.86% |
| Mar 31, 2021 | -262.89% |